260 related articles for article (PubMed ID: 33920014)
1. Degraded Arabinogalactans and Their Binding Properties to Cancer-Associated Human Galectins.
Pfeifer L; Baumann A; Petersen LM; Höger B; Beitz E; Classen B
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920014
[TBL] [Abstract][Full Text] [Related]
2. Thermodynamic binding studies of galectin-1, -3 and -7.
Brewer CF
Glycoconj J; 2002; 19(7-9):459-65. PubMed ID: 14758069
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 binds selectively to the terminal, non-reducing end of β(1→4)-galactans, with overall affinity increasing with chain length.
Miller MC; Zheng Y; Zhou Y; Tai G; Mayo KH
Glycobiology; 2019 Jan; 29(1):74-84. PubMed ID: 30204870
[TBL] [Abstract][Full Text] [Related]
4. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
5. Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
[TBL] [Abstract][Full Text] [Related]
6. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.
Stowell SR; Arthur CM; Mehta P; Slanina KA; Blixt O; Leffler H; Smith DF; Cummings RD
J Biol Chem; 2008 Apr; 283(15):10109-23. PubMed ID: 18216021
[TBL] [Abstract][Full Text] [Related]
7. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
Grosset AA; Labrie M; Vladoiu MC; Yousef EM; Gaboury L; St-Pierre Y
Oncotarget; 2016 Apr; 7(14):18183-203. PubMed ID: 26933916
[TBL] [Abstract][Full Text] [Related]
8. Quaternary solution structures of galectins-1, -3, and -7.
Morris S; Ahmad N; André S; Kaltner H; Gabius HJ; Brenowitz M; Brewer F
Glycobiology; 2004 Mar; 14(3):293-300. PubMed ID: 14693909
[TBL] [Abstract][Full Text] [Related]
9. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
Schulz H; Schmoeckel E; Kuhn C; Hofmann S; Mayr D; Mahner S; Jeschke U
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28594391
[TBL] [Abstract][Full Text] [Related]
10. Design-functionality relationships for adhesion/growth-regulatory galectins.
Ludwig AK; Michalak M; Xiao Q; Gilles U; Medrano FJ; Ma H; FitzGerald FG; Hasley WD; Melendez-Davila A; Liu M; Rahimi K; Kostina NY; Rodriguez-Emmenegger C; Möller M; Lindner I; Kaltner H; Cudic M; Reusch D; Kopitz J; Romero A; Oscarson S; Klein ML; Gabius HJ; Percec V
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2837-2842. PubMed ID: 30718416
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen.
Bian CF; Zhang Y; Sun H; Li DF; Wang DC
PLoS One; 2011; 6(9):e25007. PubMed ID: 21949831
[TBL] [Abstract][Full Text] [Related]
12. Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.
Rapoport EM; André S; Kurmyshkina OV; Pochechueva TV; Severov VV; Pazynina GV; Gabius HJ; Bovin NV
Glycobiology; 2008 Apr; 18(4):315-24. PubMed ID: 18256179
[TBL] [Abstract][Full Text] [Related]
13. Regioselective 3-O-Substitution of Unprotected Thiodigalactosides: Direct Route to Galectin Inhibitors.
Vašíček T; Spiwok V; Červený J; Petrásková L; Bumba L; Vrbata D; Pelantová H; Křen V; Bojarová P
Chemistry; 2020 Aug; 26(43):9620-9631. PubMed ID: 32368810
[TBL] [Abstract][Full Text] [Related]
14. Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
O'Sullivan JM; Jenkins PV; Rawley O; Gegenbauer K; Chion A; Lavin M; Byrne B; O'Kennedy R; Preston RJ; Brophy TM; O'Donnell JS
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):855-63. PubMed ID: 27013611
[TBL] [Abstract][Full Text] [Related]
15. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Galectin Fusion Proteins with Glycoprotein Affinity Columns and Binding Assays.
Dey C; Palm P; Elling L
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770718
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
18. Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans.
Stegmayr J; Lepur A; Kahl-Knutson B; Aguilar-Moncayo M; Klyosov AA; Field RA; Oredsson S; Nilsson UJ; Leffler H
J Biol Chem; 2016 Jun; 291(25):13318-34. PubMed ID: 27129206
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Molecular Interactions of Symmetrical and Unsymmetrical Selenoglycosides with Human Galectin-1 and Galectin-3.
Pirone L; Nieto-Fabregat F; Di Gaetano S; Capasso D; Russo R; Traboni S; Molinaro A; Iadonisi A; Saviano M; Marchetti R; Silipo A; Pedone E
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955408
[TBL] [Abstract][Full Text] [Related]
20. Galectin binding to cells and glycoproteins with genetically modified glycosylation reveals galectin-glycan specificities in a natural context.
Nielsen MI; Stegmayr J; Grant OC; Yang Z; Nilsson UJ; Boos I; Carlsson MC; Woods RJ; Unverzagt C; Leffler H; Wandall HH
J Biol Chem; 2018 Dec; 293(52):20249-20262. PubMed ID: 30385505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
